Skip to content

News & calendar

news: as of 2026-10-08
What the marks mean

Importance is a model-assigned 1–5 on published stories, not a market forecast.

Impact on a scheduled row is a company-prominence tier (High/Medium from graph centrality and size; Low only on curated minor events), not a magnitude forecast.

An earnings date marked confirmed is company-confirmed by Yahoo Finance; estimated is not yet announced. Unmarked rows carry no recorded provenance.

Economic releases are macro and carry no industry, so they stay in every view. A release with no value has not printed yet and says so rather than showing a zero.

Upcoming events across the tracked universe; past events are archived, with outcomes added where available — curated and cited, never fabricated. A past row without one reads “outcome pending”.

A lock-up or index change row adds one line of arithmetic — shares becoming sellable, or shares index funds must buy, as a share of float — read off the prospectus or the index methodology, with both numbers cited in the row. It states the mechanics, not a price move. A lock-up date derived as IPO + 180 days stays estimated until the company states it.

Ahead

scheduled · today and tomorrow · calendar refreshed 2026-10-12

Mon · 12 Oct · today

Tue · 13 Oct

Behind

published · newest first

Wed · 15 Jul

partnership

14:01
Google News: Vertex Pharmaceuticals

Vertex to Acquire Crinetics Pharmaceuticals (CRNX) in $85 Per Share Cash Deal

Vertex Pharmaceuticals agreed to acquire Crinetics Pharmaceuticals in an $85-per-share cash deal.

Markets open original ↗

partnership

14:00
Google News: GSK plc

GSK completes USD10.6 billion acquisition of Nuvalent

GSK completed its $10.6 billion acquisition of Nuvalent.

Markets open original ↗

partnership

13:40
Google News: Redwire Corporation

Redwire shares climb after securing $21.5 million U.S. defense contract (RDW)

Redwire shares climbed after the company secured a $21.5 million U.S. defense contract.

Markets open original ↗

product

12:55
Google News: Regeneron Pharmaceuticals, Inc.

Regeneron Pharmaceuticals (REGN) Stumbled In A Trial Setback, Is The Stock Still Cheap?

Regeneron suffered a clinical trial setback, according to a report questioning whether the stock remains cheap.

Markets open original ↗

funding

12:35
Google News: Vulcan Energy Resources

Vulcan Energy Draws First Tranche of €2.2bn Lionheart Funding as Lithium Headwinds Persist

Vulcan Energy drew the first tranche of its €2.2 billion Lionheart project funding.

Markets open original ↗

The wire

everything that arrived · 7 days